CTIS2023-507384-20-00进行中（未招募）1 期
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infant Subjects with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency - INZ701-104
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Caregiver(s) must provide written or electronic consent after the nature of the study has been explained, and prior to any research-related procedures, per International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)., Study participant must have a confirmed post-natal molecular genetic diagnosis of ENPP1 Deficiency with biallelic mutations (ie, homozygous or compound heterozygous) performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) certified laboratory or local equivalent, Study participant must be male or female from birth to <1 year of age at Baseline (Day 1), Study participant must weigh =0.5 kg at the time of the first dose of INZ-701, In the opinion of the Investigator, the study participant must be able to complete all aspects of the study, Study participant’s caregiver(s) must agree to provide access to their child’s relevant medical records
排除标准
- •In the opinion of the Investigator, presence of any clinically significant disease or laboratory abnormality (outside of those considered associated with the diagnosis of ENPP1 Deficiency) that precludes study participation or may confound interpretation of study results, including known uncontrolled thyroid disease or unrelated connective tissue, bone, mineral, or muscle disease, Care has been withdrawn or subject is receiving end of life care or hospice only, Known malignancy, Known intolerance to INZ-701 or any of its excipients, Concurrent participation in another non-Inozyme interventional study, Receipt of any other non-Inozyme investigational new drug within 5 half-lives of the last dose of the other investigational drug or from 4 weeks prior to the first dose of INZ-701, whichever is longer, or use of an investigational device through completion of participation in the study
研究者
相似试验
尚未招募
不适用
An Open Label, Non-randomised study to evaluate the safety, efficacy, tolerability and compliance of the Tongue Tamer Mandibular Advancement Splint in patients with Obstructive Sleep ApnoeaObstructive Sleep ApnoeaRespiratory - Sleep apnoeaACTRN12615000037505Prof. Peter Cistulli15
进行中（未招募）
不适用
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2008-008435-29-CZWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%). - NDSevere hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937EUCTR2008-008435-29-ITWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research & Development50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 14.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-008435-29-FRWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 17.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2008-008435-29-BGWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50